Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The AbbVie Immunology Scholarship provides financial support to students living with chronic, immune-mediated diseases who are pursuing higher education in the United States.
The U.S. FDA has requested some additional data from BioMarin Pharmaceuticals for the BLA it filed for the hemophilia A therapy valoctocogene roxaparvovec.
How much could a human genome cost? The answer is $100, according to newly launched biotech company Ultima Genomics, which received $600 million in backing.
The WHO reports it’s too early to tell if the monkeypox outbreak could become a pandemic, but believe there is a window of opportunity to control the cases.
Portland-based Children’s Cancer Therapy Development Institute is discovering more targeted drugs for childhood cancers and driving them into clinical development with industry partner Artisan Biopharma.
Eledon Pharmaceuticals announced positive topline results from its Phase IIa clinical trial evaluating tegoprubart in patients with amyotrophic lateral sclerosis (ALS).
BioSpace looks at the challenges faced by the Latinx community in the life sciences, from the origins of the challenges, to educational gain and the importance of mentorship.
The FDA has decided to extend the Prescription Drug User Fee Act (PDUFA) review date for TG Therapeutics’s ublituximab until December 2022.
RhoVac AB announced Tuesday that its candidate therapeutic for prostate cancer failed to meet targets in a Phase IIb study.
GSK announced that it is acquiring Affinivax for up to $3.3 billion to gain its novel class of developmental vaccines and its MAPS technology.
The ASCO Annual Meeting being held in June 3 to 7 will introduce hundreds of posters, abstracts and presentations of cancer studies, preclinical and clinical. BioSpace looks at three presenters.
The long weekend saw BMS’s Opdivo, Novartis’s Kymriah and Roche’s Evrysdi win FDA approvals in new indications.